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Activin Receptor-Like Kinase 5 Inhibitor Attenuates Fibrosis in 
Fibroblasts Derived from Peyronie’s Plaque
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Korea 
Purpose: Transforming growth factor-β1 (TGF-β1) is the key fibrogenic cytokine asso-
ciated with Peyronie’s disease (PD). The aim of this study was to determine the anti-
fibrotic effect of 3-((5-(6-Methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-yl) 
methyl)benzamide (IN-1130), a small-molecule inhibitor of the TGF-β type I receptor 
activin receptor-like kinase 5 (ALK5), in fibroblasts isolated from human PD plaque.
Materials and Methods: Plaque tissue from a patient with PD was used for primary 
fibroblast culture, and we then characterized primary cultured cells. Fibroblasts were 
pretreated with IN-1130 (10 μM) and then stimulated with TGF-β1 protein (10 ng/ml). 
We determined the inhibitory effect of IN-1130 on TGF-β1-induced phosphorylation 
of Smad2 and Smad3 or the nuclear translocation of Smad proteins in fibroblasts. 
Western blot analyses for plasminogen activator inhibitor-1, fibronectin, collagen I, 
and collagen IV were performed to evaluate effect of IN-1130 on the production of ex-
tracellular matrix proteins. 
Results: The treatment of fibroblasts with TGF-β1 significantly increased phosphor-
ylation of Smad2 and Smad3 and induced translocation of Smad proteins from the cyto-
plasm to the nucleus. Pretreatment with IN-1130 substantially inhibited TGF-β1-in-
duced phosphorylation of Smad2 and Smad3 and nuclear accumulation of Smad 
proteins. The TGF-β1-induced production of extracellular matrix proteins was also sig-
nificantly inhibited by treatment with IN-1130 and returned to basal levels.
Conclusions: Overexpression of TGF-β and activation of Smad transcriptional factors 
are known to play a crucial role in the pathogenesis of PD. Thus, inhibition of the TGF-β
signaling pathway by ALK5 inhibitor may represent a promising therapeutic strategy 
for treating PD.
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INTRODUCTION
Peyronie’s disease (PD) is a relatively common condition and 
affects 3.2 to 8.9% of the male population [1,2]. PD is charac-
terized by severe fibrotic processes in the tunica albuginea, 
which hinders expansion of the tunica albuginea and results 
in penile curvature [3]. The etiology of PD is not yet fully 
uncovered. Recent studies suggest that localized in-
flammatory processes and aberrant wound healing in the tun-
ica albuginea following minor trauma to the penis during sex-
ual intercourse are responsible for the plaque development 
[4,5]. However, the available medical treatment options, in-
cluding oral, intralesional injection, and topical therapies, 
have failed to demonstrate conclusive effects, and surgical 
treatment is currently the only efficacious treatment for PD 
[6-8]. It is necessary to understand the pathophysiologic 
mechanisms of PD at the cellular and molecular levels to de-
velop targeted and curative treatment modalities for PD. Korean J Urol 2012;53:44-49
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Overexpression of profibrotic cytokines is known to play 
an important role in the development of fibrotic plaque, and 
transforming growth factor-β1 (TGF-β1) is the most ex-
tensively studied as a candidate fibrogenic cytokine. We 
and other investigators have reported that the expression 
and activity of the TGF-β1 and Smad transcription factors 
are significantly increased in human PD plaque and in fi-
broblasts derived from patients with PD [9-11]. Moreover, 
we observed that local injection of adenovirus encoding the 
TGF-β1 gene (ad-TGF-β1) into the tunica albuginea of rats 
results in histologic and morphological changes in the tun-
ica that are similar to those found in human PD plaques 
[12], which further supports a causative role of TGF-β1 in 
the pathogenesis of PD. Therefore, targeted inhibition of 
the TGF-β signaling pathway might be a valuable ther-
apeutic strategy for the treatment of PD. Recently, small- 
molecule inhibitor of TGF-β type I receptor, activin re-
ceptor-like kinase 5 (ALK5) inhibitor, was shown to de-
crease fibrosis in kidney, lung, and liver [13-15]. We also 
recently found that local injection of an ALK5 inhibitor, 
3-((5-(6-Methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-im-
idazol-2-yl)methyl)benzamide (IN-1130), into the tunica 
albuginea induced the regression of tunical fibrosis and 
corrected penile curvature in a rat model of PD induced by 
repeated intratunical injection of ad-TGF-β1 [16]. 
In the present study, we determined the effectiveness of 
IN-1130 on the TGF-β1-induced activation of the Smad 
transcription factors and extracellular matrix production 
in fibroblasts isolated from human PD plaque. 
MATERIALS AND METHODS
1. Cell culture and characterization
Plaque tissue from a patient with PD was used for primary 
fibroblast culture. Plaque tissue was transferred into ster-
ile vials containing Hank’s balanced salt solution (Invitro-
gen, Carlsbad, CA, USA). After washing three times in 
phosphate-buffered saline (PBS), the tissue was minced in-
to 1 mm
2 segments and incubated in Dulbecco’s modified 
Eagle Medium (DMEM) supplemented with 0.06% collage-
nase A (Sigma-Aldrich Co., St. Louis, MO, USA) for 1 hour. 
After centrifugation (400 g x 5 minutes) and washing in 
fresh culture medium, the cells and tissue fragments were 
collected and placed in 100 mm cell culture dishes (BD, 
Franklin Lakes, NJ, USA) under standard conditions us-
ing DMEM supplemented with 10% fetal calf serum, pen-
icillin (100 U/ml), and streptomycin (100 μg/ml). The dishes 
were then incubated in a humidified 37
oC incubator with 
5% CO2. The study protocol was approved by the Institutio-
nal Review Board of our university.
For the characterization of primary cultured cells, the 
cells were cultured on sterile cover glass until nearly 
confluent. After serial washes with PBS, the cells were fixed 
in 4% paraformaldehyde for 10 minutes at 4
oC and in 100% 
methanol for 10 minutes at 4
oC. Individual chambers were 
incubated with antibody to vimentin (1:500; a fibroblast 
marker, Sigma-Aldrich Co.), smooth muscle α-actin (1:500; 
a myofibroblast marker, Sigma-Aldrich Co.), desmin (1:500; 
a smooth muscle cell marker, Abcam, Cambridge, UK), or 
platelet/endothelial cell adhesion molecule (PECAM-1, an 
endothelial cell marker; Chemicon, Temecula, CA, USA; 
1:500) for 1 hour at room temperature. After serial washes 
with PBS, the chambers were incubated with fluorescein 
isothiocyanate (FITC)-conjugated goat anti-mouse im-
munoglobulin (IgG) (1:1,000; Zymed Laboratories, South 
San Francisco, CA, USA) or FITC-conjugated goat an-
ti-hamster IgG (1:1,000; Jackson ImmunoReseach 
Laboratories Inc., West Grove, PA, USA) for 2 hours at room 
temperature. For the nuclei labeling, medium containing 
4,6-diamidino-2- phenylindole (DAPI, Vector Laboratories 
Inc., Burlingame, CA, USA) was applied to the chamber.
2. Western blot
IN-1130, an ALK5 inhibitor, was provided by SK Chemi-
cals (Seongnam, Korea). After serum starvation for 24 
hours, the fibroblasts were pretreated for 1 hour with 10 
μM IN-1130 (molecular weight, 518). For detection of the 
P-Smad2, total Smad2, P-Smad3, and total Smad3 pro-
teins, the fibroblasts were treated with 10 ng/ml TGF-β1 
(R&D Systems Inc., Minneapolis, MN, USA) for 1 hour, and 
for detection of the plasminogen activator inhibitor-1 
(PAI-1), fibronectin, collagen I, and collagen IV proteins, 
the cells were incubated with TGF-β1 for 24 hours. 
Cytosolic and nuclear proteins were extracted by using 
a commercially available kit (NE-PER Nuclear and Cyto-
plasmic Extraction kit; Pierce Biotechnology, Rockford, IL, 
USA). Briefly, after serial washes with PBS, the cells were 
harvested and centrifuged for 5 minutes at 3,000 rpm (4
oC). 
Cell pellets were incubated in 100 μl cytoplasmic extraction 
reagent I on ice for 10 minutes, and then 5.5 μl cytoplasmic 
extraction reagent II was added to the sample and in-
cubated on ice for 1 minute. After centrifugation for 5 mi-
nutes at 13,000 rpm (4
oC), the supernatant (cytosolic ex-
tract) was transferred to a tube on ice. Pelleted nuclei were 
resuspended in 100 μl nuclear extraction reagent on ice. 
After serial vortexes for 15 seconds every 10 minutes on ice 
for 40 minutes, the samples were centrifuged for 10 minutes 
at 13,000 rpm (4
oC) and the supernatant (nuclear extract) 
was transferred to a tube on ice. Equal amounts of each cyto-
solic and nuclear protein fraction (80 μg/lane) were sepa-
rated by 10% sodium dodecylsulfate-polyacrylamide gel 
electrophoresis and immunoblotting. After protein trans-
fer, nitrocellulose membranes were incubated with anti-
body against P-Smad2, total Smad2 (which also recognizes 
Smad3), P-Smad3 (1:300; Cell Signaling, Technology Inc., 
Danvers, MA, respectively), total Smad3 (1:300; Zymed 
Laboratories Inc.), Hsp90 (1:300; a cytosol marker, Abcam 
plc), or lamin (1:50; a nuclear marker, Abcam plc). 
Equal amounts of protein from whole-cell extracts (80 
μg/lane) were separated by 10% sodium dodecylsulfa-
te-polyacrylamide gel electrophoresis and immunoblott-
ing. After protein transfer, nitrocellulose membranes were 
incubated with antibody against PAI-1 (1:600; Abcam plc), 
fibronectin (1:300; Abcam plc), collagen I (1:300; Abcam Korean J Urol 2012;53:44-49
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FIG. 1. Characterization of primary cultured fibroblasts isolated 
from human Peyronie’s disease plaque. Fluorescent immuno-
cytochemistry of cultured cells with antibody against vimentin and 
smooth muscle α-actin (positive markers) and antibody against 
desmin and platelet/endothelial cell adhesion molecule-1 (PECAM- 
1) (negative markers). Nuclei were labeled with the DNA dye 4,6- 
dimidino-2-phenylindole (DAPI). 
aSmooth muscle α-actin is a ma-
ker for myofibroblasts. Magnification, x400. Bar indicates 100 μm.
FIG. 2. Effect of IN-1130 on TGF-β1-induced Smad2 and Smad3 
phosphorylation in fibroblasts isolated from human Peyronie’s
disease (PD) plaque. Representative Western blot for phos-
pho-Smad2 (P-Smad2), total Smad2, phospho-Smad3 (P-Smad3), 
and total Smad3. Fibroblasts were pretreated for 1 hour with 
IN-1130 (10 μM) and were then induced with TGF-β1 (10 ng/ml) for 
1 hour. Cytosolic and nuclear extracts obtained from fibroblasts 
were fractionated in a sodium dodecylsulfate-polyacrylamide gel. 
Hsp90 is a cytosolic marker and lamin is a nuclear marker used for 
determining the quality of cytosolic and nuclear extracts. Arrows 
denote target bands. Results were similar from three independent 
experiments. TGF-β1, transforming growth factor-β1. 
plc), collagen IV (1:300; Abcam plc), or β-actin (1:6,000; 
Abcam plc). Results were quantified by densitometry.
3. Nuclear translocation
The fibroblasts were cultured on sterile cover glass until 
nearly confluent. After serum starvation for 24 hours, the 
cells were pretreated for 1 hour with 10 μM IN-1130 and 
were then treated with 10 ng/ml TGF-β1 (R&D Systems 
Inc.) for 1 hour. Individual chambers were processed as de-
scribed above and were then incubated with antibody to to-
tal Smad2 (which also recognizes Smad3, 1:500; Cell Signa-
ling Inc.) for 3 hours at room temperature. After several 
washes with PBS, the chambers were incubated with 
FITC-conjugated goat anti-mouse IgG (1:1,000; Zymed 
Laboratories Inc.) for 2 hours at room temperature. For the 
nuclei labeling, medium containing DAPI (Vector Labora-
tories Inc.) was applied to the chamber. 
Digital images were captured with an Apotome micro-
scope (Zeiss, Göttingen, Germany), and fluorescent in-
tensity was measured for every nucleus in the field and 
averaged for the field with an image analyzer system 
(National Institutes of Health Image J, Bethesda, MD, 
USA). 
4. Statistical analysis
Results are expressed as means±SD. Statistical analysis 
was performed by using one-way ANOVA followed by 
Student-Newman-Keuls post-hoc tests. Values of p
＜0.05 were considered to be statistically significant. 
RESULTS
1. Isolation and characterization of primary cultured fibro-
blasts derived from human PD plaque 
More than 95% of primary cultured cells showed positive 
staining for fibroblast marker (vimentin) but did not reveal 
positive staining for antibody to desmin (smooth muscle 
cell marker) or PECAM-1 (endothelial cell marker) (Fig. 1). 
Similar to the result from a previous study [17], about 20% 
of the primary cultured cells stained positive for antibody 
to smooth muscle α-actin (myofibroblast marker) (Fig. 1).
2. Effect of IN-1130 on TGF-β1-induced phosphorylation 
of Smad2 and Smad3 in fibroblasts derived from human 
PD plaque
We determined the ability of IN-1130 to inhibit TGF-β1-in-
duced Smad2 and Smad3 phosphorylation. At 1 hour after 
treatment with recombinant TGF-β1 protein, we observed 
a profound increase in phosphorylation of Smad2 and 
Smad3 in both cytosolic and nuclear fractions. Preincuba-
tion with IN-1130 substantially inhibited phosphorylation 
of Smad2 and Smad3 (Fig. 2).
3. Effect of IN-1130 on TGF-β1-induced nuclear trans-
location of Smad2/3 in fibroblasts derived from human 
PD plaque
TGF-β1 is known to be involved in the nuclear shuttling of 
Smad2 and Smad3, i.e., the translocation of Smad proteins 
from the cytoplasm to the nucleus [18]. Therefore, we asked Korean J Urol 2012;53:44-49
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FIG. 3. Effect of 3-((5-(6-Methylpyri-
din-2-yl)-4-(quinoxalin-6-yl)-1H-imid-
azol-2-yl)methyl)benzamide (IN-1130) on
transforming growth factor-β1 (TGF- 
β1)-induced nuclear translocation of 
Smad2/3 in fibroblasts isolated from 
human Peyronie’s diseas plaque. (A) 
Fluorescent immunocytochemistry of 
primary human fibroblasts with anti-
body against total Smad2 (which also 
recognizes Smad3). Nuclei were label-
ed with the DNA dye DAPI. Fibrobla-
sts were pretreated for 1 hour with 
IN-1130 (10 μM) and were then indu-
ced with TGF-β1 (10 ng/ml) for 1 hour. 
Arrowheads denote nuclear transloca-
tion of Smad2/3. Magnification, x400. 
Bar indicates 50 μm. (B) Nuclear fluo-
rescence intensity was quantified for 
all cells. Each bar depicts the mean 
values (±SD) for n=4 per group. 
ap
＜0.01 compared with the other gro-
ups. DAPI: 4,6-diamidino-2-phenylin-
dole, TGF-β1: transforming growth 
factor-β1. Korean J Urol 2012;53:44-49
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FIG. 4. Effect of 3-((5-(6-Methylpyridin-2-yl)-4-(quinoxalin-6- 
yl)-1H-imidazol-2-yl)methyl)benzamide (IN-1130) on transfor-
ming growth factor-β1 (TGF-β1)-induced extracellular matrix 
protein production in fibroblasts isolated from human Peyro-
nie’s disease plaque. (A) Representative Western blot for PAI-1, 
fibronectin, collagen I, and collagen IV in fibroblasts. Fibro-
blasts were pretreated for 1 hour with IN-1130 (10 μM) and were 
then induced with TGF-β1 (10 ng/ml) for 24 hours. Whole-cell 
extracts were fractionated in a sodium dodecylsulfate-polya-
crylamide gel. (B) Data are presented as the relative density of 
each protein compared with that of β-actin. Each bar depicts the 
mean values (±SD) from four experiments per group. 
a: p＜0.01, 
b: p＜0.05 compared with the other groups. PAI-1: plasminogen 
activator inhibitor-1, TGF-β1: transforming growth factor-β1. 
whether ALK5 activity is necessary for TGF-β1-induced 
nuclear translocation of Smad2/3. Fluorescent im-
munocytochemistry of fibroblasts with antibody against 
total Smad2 (which also recognizes Smad3) and nuclei la-
beling with DAPI revealed that treatment with IN-1130 
significantly reduced TGF-β1-induced nuclear accumu-
lation of Smad proteins (Fig. 3). 
4. Effect of IN-1130 on TGF-β1-induced extracellular ma-
trix production in fibroblasts derived from human PD 
plaque
To evaluate the effect of ALK5 inhibition on extracellular 
matrix production, we examined the effect of IN-1130 on 
TGF-β1-induced PAI-1, fibronectin, collagen I, and colla-
gen IV expression in fibroblasts. Treatment of fibroblasts 
with TGF-β1 significantly increased the production of ex-
tracellular matrix proteins. IN-1130 significantly in-
hibited TGF-β1-induced production of extracellular ma-
trix markers. IN-1130 did not affect the basal production 
of extracellular matrix proteins in fibroblasts not stimu-
lated with TGF-β1 (Fig. 4). 
DISCUSSION
In this study, we showed that a small-molecule inhibitor 
of ALK5, IN-1130, successfully blocked TGF-β1-induced 
signaling, i.e., phosphorylation and nuclear translocation 
of Smad2 and Smad3, and inhibited extracellular matrix 
production in fibroblasts derived from human PD plaque. 
TGF-β-mediated fibrotic responses begin by activating 
the receptor-associated Smads, including Smad2 and 
Smad3 [19]. ALK5 is a TGF-β type I receptor specifically 
involved in the activation of TGF-β. TGF-β induces the 
phosphorylation of serine/threonine residues of ALK5 and 
then phosphorylates the major downstream signaling mol-
ecules Smad2 and Smad3. Phosphorylated Smad2 and 
Smad3 form a heteromeric complex with Smad4 and trans-
locate into the nucleus. When translocated, phos-
pho-Smad2 and phospho-Smad3 regulate the tran-
scription of TGF-β-responsive genes and induce tissue fib-
rosis [19]. Previous studies revealed an activation of 
Smad2 or Smad3 in the kidneys of diabetic animals [20,21], 
and targeted deletion of the Smad3 gene attenuated dia-
betes-induced renal fibrosis [22], which supports a major 
role of Smad2 and Smad3 in renal fibrosis. The activation 
of Smad2 and Smad3 in human PD plaque or in fibroblasts 
isolated from a PD patient as shown by us [11] and other 
investigators [10] indicates that inhibition of the TGF-β 
pathway may be a promising therapeutic strategy for PD. 
The phosphorylation of Smad2 or Smad3 is necessary for 
nuclear translocation and TGF-β-mediated fibrosis [23]. In 
the present study, IN-1130 substantially inhibited 
TGF-β1-induced Smad2 and Smad3 phosphorylation and 
the nuclear shuttling of Smad proteins. The ALK5 kinase 
activity affects nuclear translocation and accumulation of 
Smad transcriptional factors [24-26], which is responsible 
for activating the profibrotic genes that are involved in the 
production and deposition of extracellular matrix protein. 
Therefore, we examined whether IN-1130 can prevent the 
stimulatory effect of TGF-β1 on the production of ex-
tracellular matrix markers. A previous study of newborn 
foreskin fibroblasts and dermal fibroblasts showed that an 
ALK5 inhibitor, SB431542, inhibited the TGF-β1-induced 
expression of extracellular matrix protein [27]. Similarly, 
IN-1130 also significantly reduced TGF-β1-induced pro-
duction of PAI-1, fibronectin, collagen I, and collagen IV, 
which was comparable to the basal levels. 
In the present study, we determined the antifibrotic ef-
fect of a selective ALK5 inhibitor, IN-1130, in human PD 
fibroblasts in vitro. The current results showing the effi-
cacy of IN-1130 in primary cultured fibroblasts derived 
from human PD and our recent results in a PD animal mod-
el in vivo suggest that ALK5 inhibition may represent a 
promising option for treating this condition [16]. Korean J Urol 2012;53:44-49
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CONCLUSIONS
A small-molecule inhibitor of ALK5, IN-1130, successfully 
blocked TGF-β1-induced Smad2/3 activation and ex-
tracellular matrix production in primary fibroblasts de-
rived from human PD plaque. Overexpression of TGF-β 
and activation of Smad transcriptional factors play a cru-
cial role in the pathogenesis of PD. Thus, inhibition of 
TGF-β signaling pathway will be a promising therapeutic 
strategy for treating PD. 
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